Chelsea nose-dives on FDA negative Northera review
This article was originally published in Scrip
Executive Summary
Chelsea Therapeutics' already rough road to approval for Northera (droxidopa) may take another detour, if not hit a dead end altogether, if the FDA ultimately agrees with the negative assessments of its internal medical and statistical reviewers who examined the firm's new drug application (NDA).